Single SC administration of MAA868 induced a sustained, dose-dependent anticoagulant effect in humans. (A) Depicts the design of the FiH study, a single ascending dose, randomized, subject- and investigator-blinded, placebo-controlled study. Healthy volunteers were recruited into consecutive cohorts and administered SC injections of placebo or increasing single doses of MAA868. In addition, a cohort (cohort 5B) of severely obese but otherwise healthy subjects received a single SC dose of 240 mg. (B) Plasma total MAA868 concentration–time profile of each cohort in a semi-logarithmic view; data are expressed as geometric mean ± standard deviation. Change of aPTT (C), FXI:C (D), and FXIf levels (E) are depicted over time for each cohort; data are expressed as ratio to baseline and displayed as geometric mean ± 95% CI. BAS, baseline; EoS, end of study (day 106).